TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Jan 13, 2023 9:52am
77 Views
Post# 35220800
RE:RE:RE:Anakinra Attenuates Glioblastoma Aggressiveness
RE:RE:RE:Anakinra Attenuates Glioblastoma Aggressiveness"So why is Hunter syndrome being played up and why has xB3-004 all but disappeared from Bioasis literature? xB3-004 is likely worth far more than Hunter syndrome."
Given Biodexa's multiple clinical stage programs with $12 billion in potential markets,, the clinical stage programs naturally demand immediate attention as opposed to programs for which there are no data that are years from clinical trials. The closest Biodexa has to a clinical asset for xB3 is Hunter and that preclinical data will be presented in Q2. That BTI and Biodexa are willing to go head-to-head against Denali, which has a time-to-market advantage for Hunter of years, and given the relationship with Chiesi this may be significant. Is there new preclinical data? Has the program been changed? BTI had already presented preclinical data for Hunter from Scarpa. Is there somethng new? BTI said its strategic focus was the intersection of Lysosomal Storage Disorders, inflammation, and neurodegeneration. xB3-004 was at the intersection and mentioned for Fabry. There hasn't been any data however, to our knowledge. The strategic focus still appears to exists. Getting xB3 on a solid financial footing will be key to developing programs to data and an IND. xB3 needs money and a solid financial footing not the threat of perpetual bankruptcy and the fantasy of programs that are years from trials with no data that can't advance.